Occurrence of a Clinically Significant Thrombocytopenic Event Treatment period through interim follow-up visit (up to 16 weeks) [clinicaltrials_resource:662a10b103c25a6c19fe788782676317]
Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Occurrence of a Clinically Significant Thrombocytopenic Event Treatment period through interim follow-up visit (up to 16 weeks) [clinicaltrials_resource:662a10b103c25a6c19fe788782676317]
Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.
Bio2RDF identifier
662a10b103c25a6c19fe788782676317
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:662a10b103c25a6c19fe788782676317
measure [clinicaltrials_vocabulary:measure]
Occurrence of a Clinically Significant Thrombocytopenic Event
time frame [clinicaltrials_vocabulary:time-frame]
Treatment period through interim follow-up visit (up to 16 weeks)
description
Occurrence of one or more clin ...... gh the end of treatment visit.
identifier
clinicaltrials_resource:662a10b103c25a6c19fe788782676317
title
Occurrence of a Clinically Sig ...... low-up visit (up to 16 weeks)
@en
type
label
Occurrence of a Clinically Sig ...... a10b103c25a6c19fe788782676317]
@en